Aurora Cannabis (NYSE:ACB) Research Coverage Started at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH initiated coverage on shares of Aurora Cannabis (NYSE:ACB) in a research report released on Wednesday morning, 24/7 WallStreet reports. The brokerage issued a buy rating and a $9.00 price objective on the stock.

Several other research firms also recently issued reports on ACB. Bank of America reaffirmed a buy rating and set a C$10.00 price objective on shares of Hexo in a report on Wednesday, April 17th. Zacks Investment Research raised shares of Golub Capital BDC from a hold rating to a buy rating and set a $20.00 price objective on the stock in a report on Tuesday, July 16th. Compass Point raised shares of Realogy from a sell rating to a neutral rating in a report on Monday, July 8th. TheStreet raised shares of TELUS from a c+ rating to a b- rating in a report on Thursday, April 4th. Finally, Desjardins reaffirmed a buy rating on shares of Horizons Enhcd Inc Eqy Cl E Unt Etf in a report on Thursday, April 25th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and six have given a buy rating to the stock. The stock presently has a consensus rating of Hold and an average target price of $8.72.

ACB opened at $6.84 on Wednesday. The company has a current ratio of 2.37, a quick ratio of 1.98 and a debt-to-equity ratio of 0.10. The stock has a market capitalization of $6.94 billion, a P/E ratio of 68.40 and a beta of 2.49. Aurora Cannabis has a 52-week low of $4.05 and a 52-week high of $12.52. The firm’s fifty day moving average is $7.47.

Aurora Cannabis (NYSE:ACB) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.05). The company had revenue of $49.00 million for the quarter, compared to analysts’ expectations of $50.92 million. Aurora Cannabis had a negative net margin of 122.65% and a positive return on equity of 1.24%. As a group, sell-side analysts expect that Aurora Cannabis will post -0.23 earnings per share for the current fiscal year.

Large investors have recently bought and sold shares of the company. Moisand Fitzgerald Tamayo LLC purchased a new position in shares of Aurora Cannabis in the first quarter worth about $25,000. Financial Management Professionals Inc. raised its stake in Aurora Cannabis by 586.3% during the first quarter. Financial Management Professionals Inc. now owns 3,061 shares of the company’s stock worth $28,000 after purchasing an additional 2,615 shares during the period. Carroll Financial Associates Inc. purchased a new position in Aurora Cannabis during the first quarter worth about $27,000. Burt Wealth Advisors raised its stake in Aurora Cannabis by 1,033.3% during the first quarter. Burt Wealth Advisors now owns 3,400 shares of the company’s stock worth $31,000 after purchasing an additional 3,100 shares during the period. Finally, Mackey Komara & Dankovich LLC purchased a new position in Aurora Cannabis during the second quarter worth about $27,000. 9.00% of the stock is currently owned by hedge funds and other institutional investors.

Aurora Cannabis Company Profile

Aurora Cannabis Inc produces and distributes medical cannabis products. It is vertically integrated and horizontally diversified across various segments of the cannabis value chain, from facility engineering and design to cannabis breeding, genetics research, production, derivatives, high value-add product development, home cultivation, wholesale, and retail distribution.

See Also: What is a bull market?

Analyst Recommendations for Aurora Cannabis (NYSE:ACB)

Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.